CA2268391A1
(en)
|
1996-10-18 |
1998-04-30 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2004240704B9
(en)
*
|
2003-05-21 |
2009-10-22 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor compounds
|
MY148123A
(en)
|
2003-09-05 |
2013-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1730167B1
(en)
*
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Macrocyclic peptides active against the hepatitis c virus
|
WO2006000085A1
(en)
*
|
2004-06-28 |
2006-01-05 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
UY29016A1
(es)
*
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
ES2366478T3
(es)
*
|
2004-07-20 |
2011-10-20 |
Boehringer Ingelheim International Gmbh |
Análogos peptídicos inhibidores de la hepatitis c.
|
RU2007116265A
(ru)
|
2004-10-01 |
2008-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Ингибирование протеазы ns3-ns4a вируса hcv
|
TW201424733A
(zh)
|
2004-10-29 |
2014-07-01 |
Vertex Pharma |
劑量型式
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2606195C
(en)
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Hcv ns3 protease inhibitors
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101514463B1
(ko)
|
2005-06-08 |
2015-04-28 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI389908B
(zh)
*
|
2005-07-14 |
2013-03-21 |
Gilead Sciences Inc |
抗病毒化合物類
|
WO2007009227A1
(en)
*
|
2005-07-20 |
2007-01-25 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
EP2305697A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
CA2615896C
(en)
|
2005-08-01 |
2012-11-13 |
Merck & Co., Inc. |
Macrocyclic peptides as hcv ns3 protease inhibitors
|
CA2618682C
(en)
|
2005-08-12 |
2011-06-21 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
NZ568135A
(en)
|
2005-10-11 |
2011-06-30 |
Array Biopharma Inc |
Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
EP1991229A2
(en)
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
BRPI0709567A2
(pt)
|
2006-03-16 |
2011-07-12 |
Vertex Pharma |
inibidores deuterados de protease de hepatite c
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US20080187516A1
(en)
*
|
2006-06-06 |
2008-08-07 |
Ying Sun |
Acyclic oximyl hepatitis c protease inhibitors
|
US7728148B2
(en)
*
|
2006-06-06 |
2010-06-01 |
Enanta Pharmaceuticals, Inc. |
Acyclic oximyl hepatitis C protease inhibitors
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
UY30437A1
(es)
*
|
2006-06-26 |
2008-01-31 |
Enanta Pharm Inc |
Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
|
KR20090024834A
(ko)
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
EP2049474B1
(en)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EA017448B1
(ru)
|
2006-07-13 |
2012-12-28 |
Ачиллион Фармасьютикалз, Инк. |
4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
|
US20090035267A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Moore Joel D |
Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
|
US7635683B2
(en)
*
|
2006-08-04 |
2009-12-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl tripeptide hepatitis C virus inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US7687459B2
(en)
*
|
2006-08-11 |
2010-03-30 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis C virus protease inhibitors
|
US20080038225A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Ying Sun |
Triazolyl acyclic hepatitis c serine protease inhibitors
|
MX2009000882A
(es)
|
2006-08-17 |
2009-02-04 |
Boehringer Ingelheim Int |
Inhibidores de la polimerasa virica.
|
WO2008051475A2
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
EP2079480B1
(en)
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
CA2667032A1
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
MX2009004556A
(es)
|
2006-10-27 |
2009-07-10 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del hcv.
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2008075103A1
(en)
|
2006-12-20 |
2008-06-26 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8435984B2
(en)
|
2007-02-26 |
2013-05-07 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of HCV replication
|
EP2463285A1
(en)
|
2007-02-27 |
2012-06-13 |
Vertex Pharmaceuticals Inc. |
Co-crystals and pharmaceutical compositions comprising the same
|
AU2008219704A1
(en)
|
2007-02-27 |
2008-09-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
US20080267917A1
(en)
*
|
2007-04-26 |
2008-10-30 |
Deqiang Niu |
N-functionalized amides as hepatitis c serine protease inhibitors
|
AP2009005057A0
(en)
*
|
2007-05-10 |
2009-12-31 |
Array Biopharma Inc |
Novel peptide inhibitors of hepatitis c virus replication
|
US20090005387A1
(en)
*
|
2007-06-26 |
2009-01-01 |
Deqiang Niu |
Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
|
AP2009005073A0
(en)
|
2007-06-29 |
2009-12-31 |
Gilead Sciences Inc |
Antiviral compounds
|
MX2009013827A
(es)
|
2007-06-29 |
2010-03-01 |
Gilead Sciences Inc |
Compuestos antivirales.
|
CA2693533A1
(en)
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis c infections
|
AU2008277377B2
(en)
|
2007-07-19 |
2013-08-01 |
Msd Italia S.R.L. |
Macrocyclic compounds as antiviral agents
|
US8242140B2
(en)
|
2007-08-03 |
2012-08-14 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
MX2010002407A
(es)
*
|
2007-08-30 |
2010-03-26 |
Vertex Pharma |
Cocristales y composiciones farmaceuticas que los comprenden.
|
JP2010540549A
(ja)
|
2007-09-24 |
2010-12-24 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
ウイルス複製阻害剤としての尿素含有ペプチド
|
WO2009070689A1
(en)
*
|
2007-11-29 |
2009-06-04 |
Enanta Pharmaceuticals, Inc. |
Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
|
WO2009070692A1
(en)
*
|
2007-11-29 |
2009-06-04 |
Enanta Pharmaceuticals, Inc. |
C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
|
WO2009076166A2
(en)
*
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Oximyl hcv serine protease inhibitors
|
MX2010006210A
(es)
*
|
2007-12-05 |
2010-08-10 |
Enanta Pharm Inc |
Inhibidores de serina proteasa de hcv de tripeptido fluorado.
|
NZ585370A
(en)
|
2007-12-19 |
2012-09-28 |
Boehringer Ingelheim Int |
Viral polymerase inhibitors
|
CA2710144A1
(en)
|
2007-12-21 |
2009-07-02 |
Avila Therapeutics, Inc. |
Hcv protease inhibitors and uses thereof
|
NZ586231A
(en)
*
|
2007-12-21 |
2012-12-21 |
Avila Therapeutics Inc |
HCV protease inhibitors comprising a functionalised proline derivative
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
US8309685B2
(en)
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
US8293705B2
(en)
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
CN102036966A
(zh)
*
|
2008-01-24 |
2011-04-27 |
益安药业 |
作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
|
KR100945784B1
(ko)
|
2008-01-24 |
2010-03-08 |
한국외국어대학교 연구산학협력단 |
C형 간염 바이러스의 중합효소 ns5b를 저해하는 c형 간염 바이러스 치료제
|
CN101980719A
(zh)
*
|
2008-01-24 |
2011-02-23 |
益安药业 |
含杂芳基的三肽hcv丝氨酸蛋白酶抑制剂
|
AR070413A1
(es)
|
2008-02-04 |
2010-04-07 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de proteasa de serina
|
MX2010010276A
(es)
*
|
2008-03-20 |
2011-03-25 |
Enanta Pharm Inc |
Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
|
EA201071034A1
(ru)
|
2008-04-15 |
2011-06-30 |
Интермьюн, Инк. |
Новые макроциклические ингибиторы репликаций вируса гепатита с
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2009134624A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
US8211891B2
(en)
*
|
2008-04-30 |
2012-07-03 |
Enanta Pharmaceuticals, Inc. |
Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
ES2392611T3
(es)
|
2008-07-22 |
2012-12-12 |
Merck Sharp & Dohme Corp. |
Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN102282265B
(zh)
|
2008-11-28 |
2020-07-24 |
埃默里大学 |
用于治疗传染病和肿瘤的方法
|
PL2364309T3
(pl)
|
2008-12-10 |
2015-03-31 |
Achillion Pharmaceuticals Inc |
Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AR074670A1
(es)
|
2008-12-19 |
2011-02-02 |
Gilead Sciences Inc |
Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
|
AU2010203656A1
(en)
|
2009-01-07 |
2011-07-21 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of HCV and HIV infection
|
WO2010093843A2
(en)
|
2009-02-12 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Hcv combination therapies
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
CA2758072A1
(en)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
MX2011012155A
(es)
|
2009-05-13 |
2012-02-28 |
Enanta Pharm Inc |
Compuestos macrociclicos como inhibidores del virus de hepatitis c.
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
EP2459582B1
(en)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
US9193740B2
(en)
*
|
2009-10-19 |
2015-11-24 |
Enanta Pharmaceuticals, Inc. |
Bismacrocyclic compounds as hepatitis C virus inhibitors
|
RU2012136824A
(ru)
|
2010-01-29 |
2014-03-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы лечения вирусной инфекции гепатита с
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
WO2012009503A1
(en)
|
2010-07-14 |
2012-01-19 |
Vertex Pharmaceuticals Incorporated |
Palatable pharmaceutical composition comprising vx-950
|
SI2618831T1
(sl)
|
2010-09-21 |
2016-06-30 |
Enanta Pharmaceuticals, Inc. |
Makrociklični inhibitorji proteaze HCV na osnovi prolina
|
US9011833B2
(en)
*
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
US8951964B2
(en)
|
2010-12-30 |
2015-02-10 |
Abbvie Inc. |
Phenanthridine macrocyclic hepatitis C serine protease inhibitors
|
EP2658859A4
(en)
|
2010-12-30 |
2014-07-30 |
Enanta Pharm Inc |
MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
WO2012109646A1
(en)
|
2011-02-11 |
2012-08-16 |
Vertex Pharmaceuticals Incorporated |
Treatment of hcv in hiv infection patients
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
US20130195797A1
(en)
|
2012-01-31 |
2013-08-01 |
Vertex Pharmaceuticals Incorporated |
High potency formulations of vx-950
|
BR112015007879A2
(pt)
|
2012-10-19 |
2017-07-04 |
Bristol Myers Squibb Co |
inibidores do vírus da hepatite c
|
EP2914613B1
(en)
|
2012-11-02 |
2017-11-22 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP2914598B1
(en)
|
2012-11-02 |
2017-10-18 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(en)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
JP6342922B2
(ja)
|
2013-03-07 |
2018-06-13 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
C型肝炎ウイルス阻害剤
|
JP2016515139A
(ja)
|
2013-03-14 |
2016-05-26 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
ソバプレビルの新規の製造方法
|
US9006423B2
(en)
|
2013-03-15 |
2015-04-14 |
Achillion Pharmaceuticals Inc. |
Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
WO2014145600A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
|
BR112015023351A2
(pt)
|
2013-03-15 |
2017-07-18 |
Achillion Pharmaceuticals Inc |
forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
|
EP3089757A1
(en)
|
2014-01-03 |
2016-11-09 |
AbbVie Inc. |
Solid antiviral dosage forms
|